TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* ≥ Age 12 years at the Screening Visit.~* History of asthma for 12 months prior to the Screening Visit.~* Documented use of an inhaled corticosteroid for at least 4 weeks prior to the Screening Visit.~* Steroid-requiring patient~* patients must demonstrate (1) an FEV1 of 40% to 80% (inclusive) of predicted normal values at both the Screening and Baseline Visits and (2) documented reversibility within 12 months of the Screening Visit, defined as a ≥ 15%~Main Exclusion Criteria:~* Life-threatening asthma within the past year or during the Run-In Period.~* History of systemic (oral or injectable) corticosteroid medication within 3 months before the Screening Visit.~* An upper or lower respiratory infection within 4 weeks prior to the Screening Visit or during the Run-In Period.~* Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).~* A smoking history equivalent to 10 pack years (i.e., at least 1 pack of 20 cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).~* Current smoking history within 12 months prior to the Screening Visit.~* Previous exposure to FlutiForm

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): FlutiForm 250/10ug
- 2 (Type: ACTIVE_COMPARATOR): SKP Fluticasone 250ug
- 3 (Type: ACTIVE_COMPARATOR): Flovent Fluticasone HFA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women older than 18 years.~* Patients diagnosed with psoriatic arthritis according to the CASPAR criteria\*.~* Patients who, following the routine clinical practice, initiated treatment with apremilast 6 months (±4 weeks) before their inclusion in the study.~* Patients naive to biologic treatments.~Exclusion Criteria:~* Patients who reject to sign the informed consent.~* Patients enrolled in a clinical trial within the 4 weeks preceding the baseline visit or for the duration of apremilast treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Psoriatic Arthritis patients on Apremilast (Type: None): Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes diagnosis~* Attend one of 4 CHNSF clinics~* Ages 18 or above~* Speak English, Spanish or Cantonese~* Have a touch tone phone~* Have had one or more clinic visits in the preceding 24 months~* Will be in the SF Bay Area for the following six months~Exclusion Criteria:~* Pregnant~* Unable to provide verbal consent~* Leaving the region in the next 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATSM Intervention (Type: ACTIVE_COMPARATOR): ATSM Intervention: Automated Telephone Self-Management Support.
- WAIT LIST Control (Type: NO_INTERVENTION): WAIT LIST Control: six month Wait List.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
* Rheumatoid Arthritis (RA) for greater than 1 year from the time of initial diagnosis of RA.~* Participants must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept + Methotrexate (Type: EXPERIMENTAL): Short Term: Abatacept was dosed by weight with participants weighing \< 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants \> 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
- Placebo + Methotrexate (Type: ACTIVE_COMPARATOR): Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
- Abatacept + Methotrexate Open Label (Type: EXPERIMENTAL): Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing \< 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants \> 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness to Improve Elders' Immune and Health Status

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older~* English speaking~* If prescribed antidepressant or anxiolytic medications, must have maintained a stable regimen for eight weeks prior to enrolling~Exclusion Criteria:~* receiving immunosuppressive therapy for cancer or other diseases~* major, uncorrected sensory impairments~* cognitive deficits (MMSE \<25, or deficits deemed significant enough to interfere)~* history of a psychotic disorder, bipolar disorder, organic brain syndrome, or mental retardation~* alcohol or substance abuse within the previous year~* severe cardiovascular disease~* known allergies to shellfish

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mindfulness-Based Stress Reduction (Type: ACTIVE_COMPARATOR): Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
- Wait-list control (Type: NO_INTERVENTION): Wait-list control participants were offered MBSR training after completion of their primary assessments periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coadministration of Measles-rubella and Rotavirus Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child 9 months of age eligible for measles-rubella vaccination~* documented evidence of a primary rotavirus vaccine series with first dose between 6 and 10 weeks of age and second dose at least 4 weeks after first dose~* healthy infants free of chronic or serious medical condition as determined by history and physical examination at time of study enrollment~* parents/guardians of each participant are able to understand and follow study procedures and agree to participate in study by providing signed informed consent~Exclusion Criteria:~* hypersensitivity to any component of measles-rubella or Rotarix vaccine which would preclude administration of the vaccine~* history of intussusception, intestinal malformations, or abdominal surgery~* known history of measles and/or rubella disease~* history of previous receipt of measles and/or rubella vaccine~* use of any immunosuppressive drugs or immunoglobulin and/or blood products since birth or anticipated during study period~* current enrolment in any other intervention trial or use of any investigational drug or vaccine throughout the study period~* any participant who reports planning to leave the study area before the completion of the study~* acute diarrhea (defined as ≥3 loose stools within a 24-hour period) or vomiting (defined as projectile vomiting or any vomiting at the discretion of the clinician) at the time of enrollment or within the last 24 hours~* acute febrile illness (defined as a temperature of ≥38°C) at the time of enrollment.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 11 Months
- Healthy Volunteers: t

Study Arms:
- measles-rubella and rotavirus vaccines (Type: EXPERIMENTAL): receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
- measles-rubella vaccine (Type: ACTIVE_COMPARATOR): receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking history of at least 10 pack years~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2009)~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \>40% and \< 80% of the predicted normal value and post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last year.~* Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia.~* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Any patient with lung cancer or a history of lung cancer (within last 5 years)~* Patients with a history of certain cardiovascular co-morbid conditions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
- fluticasone/salmeterol (Type: ACTIVE_COMPARATOR): Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 2 or 3~* Had cirrhosis determination~* Prior treatment failure~* Screening laboratory values within defined thresholds~* Subject had not been treated with any investigational drug or device within 30 days of the screening visit~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV+placebo (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
- SOF+RBV (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females aged 18\~65 years~2. De novo recipients of cadaveric, living unrelated or living related donor kidney transplants~3. Received kidney transplant from aged 10\~65years donor~4. Willing to provide written informed consent~5. Completing study visits according to study protocol~Exclusion Criteria:~1. Recipients of multiple organ transplants~2. Kidney transplant from non-heart beating cadaveric donor / organ donor after cardiac death~3. Recipients of A-B-O incompatible transplants or lymphocyte cross-match positive transplants~4. Recipients of extra-renal solid organ transplants or stem cell transplants~5. Recipient/ donor who are known to have anti-HCV, HIV or HBsAg positive~6. Diagnosed as Cancer within the past 5 years (except complete recovered squamous cell or basal cell skin cancer)~7. Drug Hypersensitivity to investigational drugs or related drugs Females are pregnant and lactating~8. Any of the following laboratory abnormalities at screening:~   * ALT, AST, ALP, total bilirubin \> 3 times the upper limit~  * ANC \< 1,500mm3 or WBC \< 2,500mm3 or platelet \< 100,000 mm3~  * Cholesterol \> 350 mg/dl or 9.0 mmol/L, TG \> 500 mg/dl or 5.6mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus + Low dose CsA +PD (Type: EXPERIMENTAL): None
- Myfortic+ Standard CsA + PD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Moderately to severely active Rheumatoid arthritis (RA) for at least 6 months, which is not adequately controlled by non-biologics DMARDs.~* No contraindications to anti-Tumor necrosis factor (TNF) agents.~* Either biologics naive or biologics-experienced but with no experience of self-administration medication using autoinjector or pen.~* Patients must be able and willing to self-inject BI 695501. Further inclusion criteria apply.~Exclusion criteria:~* Experience with self-administration of medication using an autoinjector or pen.~* American College of Rheumatology functional Class IV or wheelchair/ bed bound.~* Primary or secondary immunodeficiency.~* History of tuberculosis (TB). Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 695501 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of adult onset Rheumatoid Arthritis (RA) in line with the protocol~* Moderately active disease in line with the protocol~* A pre-defined number of swollen joints in line with the protocol~* Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)~* No evidence of respiratory disease.~Exclusion Criteria:~* A rheumatic autoimmune disease other than RA, or significant systemic extra-articular involvement secondary to RA~* A history of, or current, inflammatory joint disease other than RA~* Previous treatment with the investigational drug~* Discontinuation of a biologic DMARD due to lack of efficacy~* Non-compliant concurrent medications~* Non-compliance with medical history criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram \[mg\] per week) through oral or parenteral route.
- Mavrilimumab 30 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
- Mavrilimumab 100 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
- Mavrilimumab 150 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RHA® 4 With New Anesthetic - Nasolabial Folds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatient, male or female of any race, 22 years of age or older. Female subjects of childbearing potential must have a negative UPT at Visit 1 and practice a reliable method of contraception throughout the study.~2. Moderate to severe bilateral nasolabial folds (grade 3 or 4 on the five-point WSRS).~3. Nasolabial folds of the same WSRS grade on the left and right sides of the face.~4. Able to follow study instructions and complete all required visits.~5. Sign the IRB-approved ICF, Photographic Release Form, the Authorization for Use and release of Health and Research Study Information (HIPAA) form, and if applicable the California Experimental Research Subject's Bill of Rights prior to any study-related procedures being performed.~Exclusion Criteria:~1. Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.~2. Known hypersensitivity or previous allergic reaction to any component of the study devices.~3. Use of a prohibited treatment/procedure within time periods defined in the protocol~4. Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.~5. History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study.~6. History of connective tissue disease.~7. Malignancy (excluding non-melanoma skin cancer) within the past 5 years.~8. History of skin cancer in the treatment area.~9. Clinically active disease or infection in the NLF area.~10. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results or compliance of the subject and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.~11. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.~12. Exposure to any other investigational drug/device within 90 days of entering the study.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RHA®4 with new anesthetic agent (Type: EXPERIMENTAL): Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side.
- RHA®4-Lidocaine (Type: EXPERIMENTAL): Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete